Male fertility is preserved following ixekizumab treatment—a real-life pilot study
In our limited-size pilot study on SpA and PsO patients, IXE exposure did not impair male fertility. Sperm parameters remained within normal ranges after a minimum of 6 months of treatment. Early IXE treatment may preserve or potentially reverse fertility impairment.
Authors
- Mihaela Micu (ORCID: https://orcid.org/0000-0003-3239-5628)
- Lorenzo Dagna (ORCID: https://orcid.org/0000-0002-7428-315X)
- Marinela Gîrlovanu
- H. Decean
- Alexandru Micu (ORCID: https://orcid.org/0000-0002-0154-1760)
- Stela Surd
- Nicola Farina (ORCID: https://orcid.org/0000-0001-7650-2582)
- Bianca Andone-Rotaru
Institutions
- Vita-Salute San Raffaele University (IT)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Babeș-Bolyai University (RO)
- Spitalul Clinic CF Cluj-Napoca (RO)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1093/rheumatology/keae609
- Primary Topic
- Sperm and Testicular Function
- Type
- article
- Field-Weighted Citation Impact
- 0.00